{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:45:49Z","timestamp":1778507149610,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1245\/s10434-024-14890-0","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T19:02:55Z","timestamp":1706986975000},"page":"3314-3324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Analysis from the US HIPEC Collaborative"],"prefix":"10.1245","volume":"31","author":[{"given":"Nadege T.","family":"Fackche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan K.","family":"Schmocker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Nudotor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boateng","family":"Kubi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan M.","family":"Cloyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Travis E.","family":"Grotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith F.","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean P.","family":"Dineen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jula","family":"Veerapong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel M.","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Callisia N.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer H.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory C.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura A.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Pokrzywa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byrne","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles A.","family":"Staley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Y.","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian M.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8968-9710","authenticated-orcid":false,"given":"Jonathan B.","family":"Greer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,3]]},"reference":[{"issue":"2","key":"14890_CR1","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/01.sla.0000197702.46394.16","volume":"243","author":"MJ Koppe","year":"2006","unstructured":"Koppe MJ, Boerman OC, Oyen WJG, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin. Ann Surg. 2006;243(2):212\u201322. https:\/\/doi.org\/10.1097\/01.sla.0000197702.46394.16.","journal-title":"Ann Surg"},{"issue":"6","key":"14890_CR2","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.21037\/jgo.2019.01.36","volume":"10","author":"SY Yang","year":"2019","unstructured":"Yang SY, Kang JH, Kim HS, Han YD, Min BS, Lee KY. Status of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. J Gastrointest Oncol. 2019;10(6):1251\u201365. https:\/\/doi.org\/10.21037\/jgo.2019.01.36.","journal-title":"J Gastrointest Oncol"},{"issue":"13","key":"14890_CR3","doi-asserted-by":"publisher","first-page":"9073","DOI":"10.1245\/s10434-021-10190-z","volume":"28","author":"C Bakkers","year":"2021","unstructured":"Bakkers C, Lurvink RJ, Rijken A, et al. Treatment strategies and prognosis of patients with synchronous or metachronous colorectal peritoneal metastases: a population-based study. Ann Surg Oncol. 2021;28(13):9073. https:\/\/doi.org\/10.1245\/s10434-021-10190-z.","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"14890_CR4","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737\u201343. https:\/\/doi.org\/10.1200\/JCO.2003.04.187.","journal-title":"J Clin Oncol"},{"key":"14890_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12885-015-1430-7","volume":"15","author":"CEL Klaver","year":"2015","unstructured":"Klaver CEL, Musters GD, Bemelman WA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer. 2015;15:428. https:\/\/doi.org\/10.1186\/s12885-015-1430-7.","journal-title":"BMC Cancer"},{"issue":"53","key":"14890_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejca.2015.09.017","volume":"2016","author":"PH Cashin","year":"1990","unstructured":"Cashin PH, Mahteme H, Sp\u00e5ng N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer Oxf Engl. 1990;2016(53):155\u201362. https:\/\/doi.org\/10.1016\/j.ejca.2015.09.017.","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"9","key":"14890_CR7","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426\u201332. https:\/\/doi.org\/10.1245\/s10434-008-9966-2.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"14890_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/BF01274232","volume":"373","author":"PH Sugarbaker","year":"1988","unstructured":"Sugarbaker PH. Surgical management of peritoneal carcinosis: diagnosis, prevention and treatment. Langenbecks Arch Chir. 1988;373(3):189\u201396. https:\/\/doi.org\/10.1007\/BF01274232.","journal-title":"Langenbecks Arch Chir"},{"issue":"2","key":"14890_CR9","first-page":"256","volume":"40","author":"JS Spratt","year":"1980","unstructured":"Spratt JS, Adcock RA, Muskovin M, Sherrill M, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40(2):256\u201360","journal-title":"Cancer Res"},{"issue":"6","key":"14890_CR10","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/SLA.0b013e3181a45d86","volume":"249","author":"JS Chua","year":"2009","unstructured":"Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009;249(6):900\u20137.","journal-title":"Ann Surg"},{"issue":"8","key":"14890_CR11","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1245\/s10434-014-4297-y","volume":"22","author":"GA Simkens","year":"2015","unstructured":"Simkens GA, van Oudheusden TR, Luyer MD, et al. Serious postoperative complications affect early recurrence after cytoreductive surgery and HIPEC for Colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2015;22(8):2656\u201362. https:\/\/doi.org\/10.1245\/s10434-014-4297-y.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"14890_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/jso.23749","volume":"110","author":"S Ahmed","year":"2014","unstructured":"Ahmed S, Stewart JH, Shen P, Votanopoulos KI, Levine EA. Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis. J Surg Oncol. 2014;110(5):575\u201384. https:\/\/doi.org\/10.1002\/jso.23749.","journal-title":"J Surg Oncol"},{"issue":"1","key":"14890_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1245\/s10434-019-07626-y","volume":"27","author":"MY Zaidi","year":"2020","unstructured":"Zaidi MY, Lee RM, Gamboa AC, et al. Preoperative risk score for predicting incomplete cytoreduction: a 12-institution study from the US HIPEC collaborative. Ann Surg Oncol. 2020;27(1):156\u201364. https:\/\/doi.org\/10.1245\/s10434-019-07626-y.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"14890_CR14","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1097\/SLA.0b013e318254f281","volume":"256","author":"PH Cashin","year":"2012","unstructured":"Cashin PH, Graf W, Nygren P, Mahteme H. Patient selection for cytoreductive surgery in colorectal peritoneal carcinomatosis using serum tumor markers: An observational cohort study. Ann Surg. 2012;256(6):1078\u201383. https:\/\/doi.org\/10.1097\/SLA.0b013e318254f281.","journal-title":"Ann Surg"},{"issue":"1","key":"14890_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/jso.21169","volume":"99","author":"JOW Pelz","year":"2009","unstructured":"Pelz JOW, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009;99(1):9\u201315. https:\/\/doi.org\/10.1002\/jso.21169.","journal-title":"J Surg Oncol"},{"issue":"12","key":"14890_CR16","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1245\/s10434-017-6042-9","volume":"24","author":"K Demey","year":"2017","unstructured":"Demey K, Wolthuis A, de van Buck Overstraeten A, et al. External validation of the prognostic nomogram (COMPASS) for patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2017;24(12):3604\u20138. https:\/\/doi.org\/10.1245\/s10434-017-6042-9.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"14890_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(20)30599-4.","journal-title":"Lancet Oncol"},{"issue":"43","key":"14890_CR18","first-page":"160","volume":"49","author":"WS Wang","year":"2002","unstructured":"Wang WS, Lin JK, Chiou TJ, et al. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer. Hepatogastroenterology. 2002;49(43):160\u20134.","journal-title":"Hepatogastroenterology"},{"issue":"4","key":"14890_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4174\/jkss.2013.84.4.231","volume":"84","author":"H Yu","year":"2013","unstructured":"Yu H, Son GM, Joh YG. The clinical significance of preoperative serum levels of carbohydrate antigen 19\u20139 in colorectal cancer. J Korean Surg Soc. 2013;84(4):231\u20137. https:\/\/doi.org\/10.4174\/jkss.2013.84.4.231.","journal-title":"J Korean Surg Soc"},{"issue":"12","key":"14890_CR20","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1245\/s10434-008-0168-8","volume":"15","author":"R Takagawa","year":"2008","unstructured":"Takagawa R, Fujii S, Ohta M, et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol. 2008;15(12):3433\u20139. https:\/\/doi.org\/10.1245\/s10434-008-0168-8.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"14890_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1967\/s002449910505","volume":"20","author":"M Stojkovic Lalosevic","year":"2017","unstructured":"Stojkovic Lalosevic M, Stankovic S, Stojkovic M, et al. Can preoperative CEA and CA19-9 serum concentrations suggest metastatic disease in colorectal cancer patients? Hell J Nucl Med. 2017;20(1):41\u20135. https:\/\/doi.org\/10.1967\/s002449910505.","journal-title":"Hell J Nucl Med"},{"issue":"2","key":"14890_CR22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.21873\/anticanres.11391","volume":"37","author":"M Kaneko","year":"2017","unstructured":"Kaneko M, Ishihara S, Murono K, et al. Carbohydrate antigen 19\u20139 predicts synchronous peritoneal carcinomatosis in patients with colorectal cancer. Anticancer Res. 2017;37(2):865\u201370. https:\/\/doi.org\/10.21873\/anticanres.11391.","journal-title":"Anticancer Res"},{"issue":"1","key":"14890_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s003840050188","volume":"14","author":"TA Rockall","year":"1999","unstructured":"Rockall TA, McDonald PJ. Carcinoembryonic antigen: its value in the follow-up of patients with colorectal cancer. Int J Colorectal Dis. 1999;14(1):73\u20137. https:\/\/doi.org\/10.1007\/s003840050188.","journal-title":"Int J Colorectal Dis"},{"issue":"6","key":"14890_CR24","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1245\/s10434-020-08315-x","volume":"27","author":"FJ Izquierdo","year":"2020","unstructured":"Izquierdo FJ, Schuitevoerder D, Plana A, et al. The Chicago Consensus on peritoneal surface malignancies: management of colorectal metastases. Ann Surg Oncol. 2020;27(6):1761\u20137. https:\/\/doi.org\/10.1245\/s10434-020-08315-x.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"14890_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32\u20135.","journal-title":"Cancer"},{"issue":"5","key":"14890_CR26","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.1651-2227.2006.00178.x","volume":"96","author":"AK Akobeng","year":"1992","unstructured":"Akobeng AK. 2007 Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr Oslo Nor. 1992;96(5):644\u20137. https:\/\/doi.org\/10.1111\/j.1651-2227.2006.00178.x.","journal-title":"Acta Paediatr Oslo Nor"},{"key":"14890_CR27","doi-asserted-by":"publisher","first-page":"3762651","DOI":"10.1155\/2017\/3762651","volume":"2017","author":"I Unal","year":"2017","unstructured":"Unal I. Defining an optimal cut-point Value in ROC analysis: an alternative approach. Comput Math Methods Med. 2017;2017:3762651. https:\/\/doi.org\/10.1155\/2017\/3762651.","journal-title":"Comput Math Methods Med"},{"issue":"3","key":"14890_CR28","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3390\/jcm9030748","volume":"9","author":"EW Beal","year":"2020","unstructured":"Beal EW, Suarez-Kelly LP, Kimbrough CW, et al. Impact of neoadjuvant chemotherapy on the outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a multi-institutional retrospective review. J Clin Med. 2020;9(3):748. https:\/\/doi.org\/10.3390\/jcm9030748.","journal-title":"J Clin Med"},{"issue":"8","key":"14890_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamasurg.2021.1642","volume":"156","author":"KP Rovers","year":"2021","unstructured":"Rovers KP, Bakkers C, Nienhuijs SW, et al. Perioperative systemic therapy vs cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases. JAMA Surg. 2021;156(8):1\u201312. https:\/\/doi.org\/10.1001\/jamasurg.2021.1642.","journal-title":"JAMA Surg"},{"issue":"3","key":"14890_CR30","first-page":"21","volume":"30","author":"R Kannagi","year":"2007","unstructured":"Kannagi R. Carbohydrate antigen sialyl Lewis a-its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med J. 2007;30(3):21.","journal-title":"Chang Gung Med J"},{"issue":"3","key":"14890_CR31","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1349-7006.2009.01455.x","volume":"101","author":"R Kannagi","year":"2010","unstructured":"Kannagi R, Sakuma K, Miyazaki K, et al. Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia: clues in the ongoing search for new tumor markers. Cancer Sci. 2010;101(3):586\u201393. https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01455.x.","journal-title":"Cancer Sci"},{"issue":"2","key":"14890_CR32","first-page":"354","volume":"53","author":"A Takada","year":"1993","unstructured":"Takada A, Ohmori K, Yoneda T, et al. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res. 1993;53(2):354\u201361.","journal-title":"Cancer Res"},{"issue":"13","key":"14890_CR33","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1158\/0008-5472.CAN-03-3614","volume":"64","author":"K Miyazaki","year":"2004","unstructured":"Miyazaki K, Ohmori K, Izawa M, et al. Loss of disialyl Lewis(a), the ligand for lymphocyte inhibitory receptor sialic acid-binding immunoglobulin-like lectin-7 (Siglec-7) associated with increased sialyl Lewis(a) expression on human colon cancers. Cancer Res. 2004;64(13):4498\u2013505. https:\/\/doi.org\/10.1158\/0008-5472.CAN-03-3614.","journal-title":"Cancer Res"},{"key":"14890_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.csda.2013.07.015","volume":"69","author":"M Rota","year":"2014","unstructured":"Rota M, Antolini L. Finding the optimal cut-point for Gaussian and Gamma distributed biomarkers. Comput Stat Data Anal. 2014;69:1\u201314. https:\/\/doi.org\/10.1016\/j.csda.2013.07.015.","journal-title":"Comput Stat Data Anal"},{"issue":"6","key":"14890_CR35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ejso.2012.03.001","volume":"38","author":"PH Cashin","year":"2012","unstructured":"Cashin PH, Graf W, Nygren P, Mahteme H. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study. Eur J Surg Oncol EJSO. 2012;38(6):509\u201315. https:\/\/doi.org\/10.1016\/j.ejso.2012.03.001.","journal-title":"Eur J Surg Oncol EJSO"},{"issue":"4","key":"14890_CR36","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1245\/ASO.2004.08.014","volume":"11","author":"VJ Verwaal","year":"2004","unstructured":"Verwaal VJ, Boot H, Aleman BMP, van Tinteren H, Zoetmulder FAN. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. Ann Surg Oncol. 2004;11(4):375\u20139. https:\/\/doi.org\/10.1245\/ASO.2004.08.014.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"14890_CR37","first-page":"1041","volume":"36","author":"YR Huo","year":"2016","unstructured":"Huo YR, Huang Y, Liauw W, Zhao J, Morris DL. Prognostic value of carcinoembryonic antigen (CEA), AFP, CA19-9 and CA125 for patients with colorectal cancer with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Anticancer Res. 2016;36(3):1041\u20139.","journal-title":"Anticancer Res"},{"issue":"7","key":"14890_CR38","first-page":"1608","volume":"13","author":"T Wu","year":"2020","unstructured":"Wu T, Mo Y, Wu C. Prognostic values of CEA, CA19-9, and CA72-4 in patients with stages I-III colorectal cancer. Int J Clin Exp Pathol. 2020;13(7):1608\u201314.","journal-title":"Int J Clin Exp Pathol"},{"issue":"6","key":"14890_CR39","first-page":"192","volume":"29","author":"S Hou","year":"2023","unstructured":"Hou S, Jing J, Wang Y, et al. Evaluation of clinical diagnostic and prognostic value of preoperative serum carcinoembryonic antigen, CA19-9, and CA24-2 for colorectal cancer. Altern Ther Health Med. 2023;29(6):192\u20137.","journal-title":"Altern Ther Health Med"},{"issue":"6","key":"14890_CR40","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s00423-021-02236-3","volume":"406","author":"H Mizuno","year":"2021","unstructured":"Mizuno H, Miyake H, Nagai H, et al. Optimal cutoff value of preoperative CEA and CA19-9 for prognostic significance in patients with stage II\/III colon cancer. Langenbecks Arch Surg. 2021;406(6):1987\u201397. https:\/\/doi.org\/10.1007\/s00423-021-02236-3.","journal-title":"Langenbecks Arch Surg"},{"issue":"3","key":"14890_CR41","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","volume":"30","author":"J Franko","year":"2012","unstructured":"Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(3):263\u20137. https:\/\/doi.org\/10.1200\/JCO.2011.37.1039.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"14890_CR42","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1007\/s11605-021-04953-y","volume":"25","author":"N Fackche","year":"2021","unstructured":"Fackche N, Schmocker RK, Kubi B, et al. The utility of preoperative tumor markers in peritoneal carcinomatosis from primary appendiceal adenocarcinoma: an Analysis from the US HIPEC collaborative. J Gastrointest Surg. 2021;25(11):2908\u201319. https:\/\/doi.org\/10.1007\/s11605-021-04953-y.","journal-title":"J Gastrointest Surg"},{"key":"14890_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2020.11.006","volume":"37","author":"JT Wiseman","year":"2021","unstructured":"Wiseman JT, Abdel-Misih S, Beal EW, et al. A multi-institutional analysis of textbook outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies. Surg Oncol. 2021;37:101492. https:\/\/doi.org\/10.1016\/j.suronc.2020.11.006.","journal-title":"Surg Oncol"},{"issue":"3","key":"14890_CR44","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.amjsurg.2019.09.017","volume":"219","author":"EW Beal","year":"2020","unstructured":"Beal EW, Ahmed A, Grotz T, et al. Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Am J Surg. 2020;219(3):478\u201383. https:\/\/doi.org\/10.1016\/j.amjsurg.2019.09.017.","journal-title":"Am J Surg"},{"issue":"6","key":"14890_CR45","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/jso.21679","volume":"102","author":"PH Sugarbaker","year":"2010","unstructured":"Sugarbaker PH, Bijelic L, Chang D, Yoo D. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol. 2010;102(6):576\u201381. https:\/\/doi.org\/10.1002\/jso.21679.","journal-title":"J Surg Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-14890-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-14890-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-14890-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T16:06:17Z","timestamp":1712333177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-14890-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,3]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["14890"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-14890-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,3]]},"assertion":[{"value":"16 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}